Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcifar
- Development stage
- Unknown
- Lead developer
- Farabi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Calcifar is an oral dietary supplement developed and manufactured by Farabi Pharmaceutical. It is formulated as an enteric-coated tablet containing a combination of calcium carbonate, magnesium oxide, zinc gluconate, and cholecalciferol (vitamin D3). Calcifar is designed to support bone health and is approved for the prevention and treatment of bone loss (osteoporosis), weak bones (osteomalacia and rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and latent tetany, particularly during pregnancy and menopause.
- Brand names
- Calcifar
- Other names
- Ca, Mg, Zn, D3calcium + magnesium + zinc + cholecalciferolcalcium + magnesium + zinc + vitamin D3calcium carbonate + magnesium oxide + zinc gluconate + cholecalciferol
02
Targets
CaSR (Extracellular calcium-sensing receptor)
Beyond the preview
Go deeper on Calcifar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calcifar.